IRCT20210901052358N1 IRCT 2022-01-03 Shahid Beheshti University of Medical Sciences The Therapeutic Effect of Molnupiravir in COVID-19 Patients Evaluation of the Efficacy of Molnupiravir on Clinical and Laboratory Findings of Patients with moderate COVID-19 2022-03-21 anticipated 60 Complete https://irct.ir/trial/60723 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization method is a simple randomization that is done in the form of individual random units. The tool used to do this is a random numbers table. The method of constructing a random sequence is that first the researcher selects one of the numbers with his eyes closed and then moves in the right direction. Odd numbers are considered for intervention and even numbers are for control. Random concealment is also performed using sequentially numbered sealed opaque envelopes (SNOSE), Blinding description: In this study, patients and physicians who play the role of prescribing medication and evaluating clinical symptoms will be unaware of the classification of patients into intervention and placebo groups (double-blind). Others, including methodologist, statistics specialist, nurses, authors of manuscript, and study designers, will be aware of the classification of patients into the two groups. 3 COVID-19. Intervention 1: Intervention group: Patients in the intervention group, in addition to standard medication (serum therapy, analgesics, antipyretic, and vitamine), take oral Molnupiravir at a dose of 800 mg every 12 hours for 5 days. Molnupiravir is prepared by Mana Teb Daya Company. Intervention 2: Control group: Patients in the control group, in addition to standard medication (serum therapy, analgesics, antipyretic, and vitamine), take oral placebo every 12 hours for 5 days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information